Network running HIV vaccine and antibody prevention trials
HIV Vaccines Clinical Trials Network Leadership and Operations Center
This program tests new vaccine shots and monoclonal antibodies to help prevent HIV infection in adults and HIV‑exposed infants at risk.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11239085 on NIH RePORTER |
What this research studies
If you join, researchers will offer experimental vaccine regimens and monoclonal antibody infusions designed to teach the immune system to make broadly neutralizing antibodies (bnAbs). The program uses sequential immunizations and B‑cell sequencing to track and steer the antibody response toward durable protective bnAbs. Trials are run through a coordinated Leadership and Operations Center that supports many U.S. and international clinical sites so studies can move quickly in high‑incidence communities. Results from early vaccine and antibody efficacy trials guide which candidates are advanced into phase 1 and later studies.
Who could benefit from this research
Good fit: Ideal candidates are people at risk for HIV infection — including adults and HIV‑exposed infants in high‑incidence areas — who meet the study's health and eligibility criteria.
Not a fit: People already living with HIV are unlikely to benefit directly from these prevention trials, and individuals with disqualifying health conditions or other exclusion criteria may not be eligible.
Why it matters
Potential benefit: If successful, this work could lead to a vaccine or antibody prevention method that substantially reduces new HIV infections.
How similar studies have performed: Previous HVTN trials have shown that broadly neutralizing antibodies can prevent HIV infection, while earlier vaccine approaches did not reliably elicit those bnAbs, so this program builds on both successes and remaining challenges.
Where this research is happening
Seattle, United States
- Fred Hutchinson Cancer Center — Seattle, United States (Active)
Researchers
- Principal investigator: Corey, Lawrence — Fred Hutchinson Cancer Center
- Study coordinator: Corey, Lawrence
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.